TABLE 4.
Measure | HC | MCI | DAT |
---|---|---|---|
No. | 10 | 7 | 10 |
Baseline | 1.89±0.27 | 2.56±0.46 | 2.40±0.29 |
20-month follow-up | 1.93±0.31 | 2.61±0.50 | 2.50±0.29 |
38-month follow-up | 2.06±0.28 | 2.74±0.49 | 2.50±0.29 |
ΔSUVR20-B | 0.04 | 0.05 | 0.10 |
Δ% | 2.1% | 1.9% | 4.2% |
p | NS | NS | 0.03 |
ΔSUVR38-B | 0.17 | 0.18 | 0.10 |
Δ% | 8.9% | 7.0% | 4.2% |
p | 0.001 | 0.0009 | 0.05 |
ΔSUVR38-20 | 0.13 | 0.13 | 0.00 |
Δ% | 6.7% | 5.0% | 0.0% |
p | 0.009 | NS | NS |
PiB = [11C]Pittsburgh compound B; SUVR = standardized uptake value ratio; HC = healthy control; MCI = mild cognitive impairment; DAT = dementia of the Alzheimer type; NS = not significant.